Digital lifestyle management application (levidex) for empowerment and health behaviour change in early multiple sclerosis – Results of the randomised controlled POWER@MS1 trial.

Veröffentlicht: von & gespeichert unter Allgemein.

Background: This randomised controlled trial investigated the effect of a personalised digital lifestyle management application (‚levidex‘) on inflammatory disease activity in newly diagnosed people with MS (pwMS), compared to a non-personalised application (‚dexilev‘) that covered similar lifestyle-related content. Methods: Participants (N = 234) were recruited from July 2019 to April 2022 in 20 study centres… Read more »

Neurobehavioral mechanisms of fear and anxiety in multiple sclerosis.

Veröffentlicht: von & gespeichert unter Allgemein.

Background: Anxiety is a common yet often underdiagnosed and undertreated comorbidity in multiple sclerosis (MS). While altered fear processing is a hallmark of anxiety in other populations, its neurobehavioral mechanisms in MS remain poorly understood. This study investigates the extent to which neurobehavioral mechanisms of fear generalization contribute to anxiety in MS. Methods: We recruited… Read more »

Heated tobacco product use prevalence and temporal trends among the German population: a series of representative cross-sectional household surveys, 2018-2023

Veröffentlicht: von & gespeichert unter Allgemein.

Objectives: Heated tobacco products (HTPs) are electronic devices that heat tobacco instead of burning it to produce an inhalable aerosol. This study aimed to investigate usage patterns, sociodemographic and socioeconomic factors, as well as co-use characteristics of people who use HTPs within the German population to inform interventions and preventive measures. Methods: We conducted analysis… Read more »

HLA-A*03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis.

Veröffentlicht: von & gespeichert unter Allgemein.

„Background: Glatiramer acetate (GA) is a well-tolerated treatment for multiple sclerosis (MS) and comparable in its efficacy to high-dose interferon beta (IFN). As a lack of validated treatment response biomarkers for MS hampers progress in personalised treatment, the study goal was to search for biomarkers of a successful treatment response utilising the known observation of… Read more »

Mental health outcomes in pregnant women with relapsing-remitting multiple sclerosis: an longitudinal cohort study.

Veröffentlicht: von & gespeichert unter Allgemein.

Introduction: Since multiple sclerosis (MS) primarily affects women of childbearing age, the disease intersects with a critical period for family planning and pregnancy. This is important, since pregnancy itself can influence psychological well-being, contributing to symptoms such as depression, stress and fatigue. However, while mental health during late pregnancy and the postpartum period has been… Read more »